With the business potentially at an important milestone, we thought we'd take a closer look at Candel Therapeutics, Inc.'s ...

Shares of Candel Therapeutics Inc. (CADL) surged over 9% on Friday morning, reaching their highest level in nearly a month ...

Candel Therapeutics' CAN-2409 shows robust, multi-cancer efficacy with significant survival gains in prostate, pancreatic, and lung cancers, plus promising early glioblastoma data. The company is ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. "We recently ...

Candel Therapeutics is taking difficult measures to keep its clinical flame burning, laying off 50% of its team as part of a wide scale restructuring meant to save cash for a couple of core programs.

An announcement from Candel Therapeutics ( (CADL)) is now available. Candel Therapeutics has reported promising results from its ongoing phase 1b clinical trial of CAN-3110 in recurrent high-grade ...

Candel Therapeutics, Inc. has announced an underwritten public offering to raise $80 million through the sale of its common stock and pre-funded warrants. The company plans to use the proceeds to ...

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday potentially driven by continued momentum following the company’s announcement of positive phase 3 trial results for its ...

NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ("Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...